Microsoft’s artificial intelligence tool BioEmu can predict the multiple conformational states of a protein, giving insight into how a protein moves and its potential function.

Google DeepMind subsidiary, Isomorphic Labs, has said it is ready to conduct human trials for drugs developed using its AlphaFold AI technology.

Alphabet's AI drug development subsidiary Isomorphic Labs is aiming to initiate clinical trials for its AI-developed oncology ...

A secretive, Google-backed lab is using artificial intelligence to invent new medicines for humanity's worst illnesses. But ...

A newly developed generative AI model is helping researchers explore protein dynamics with increased speed. The deep learning system, called BioEmu, predicts the full range of conformations a protein ...

Isomorphic Labs is preparing to test AI-designed drugs in humans, marking a new phase in drug development with artificial ...

One day we hope to be able to say — well, here’s a disease, and then click a button and out pops the design for a drug to ...

Beware the tech leaders making grandiose statements about artificial intelligence. They have lost sight of reality, says ...

The start-up, which aims to raise tens of millions of US dollars in an angel funding round, hopes to compete globally, ...

Alphabet’s Isomorphic Labs is preparing to begin human trials of a drug designed using AI, based on protein modelling ...

Now Google’s DeepMind division says it’s made a leap in trying to understand the code with AlphaGenome, an AI model that ...